Arkema's Stock Stalls Below Its Moving Average, Sliding Over 2%
The specialty chemicals company retreats during the session while the SBF 120 remains well-oriented. The stock loses ground after recently hitting a resistant technical threshold. This movement occurs away from the drivers of the Paris session, dominated by technology and luxury stocks.
Arkema Falters in an SBF 120 Boosted by Tech and Luxury
Arkema's stock falls by 2.38% to €61.55, while the SBF 120 index rises by 0.84% and the CAC 40 gains 0.91%. The stock ranks 109th out of 120 in the broader index, going against the grain of a session led by Rémy Cointreau (+11.57%), Abivax (+11.51%), and Capgemini (+6.66%).
The decline partially erases the rebound that began at the end of May, when the stock had recovered nearly 2% by retesting its 20-day moving average, as mentioned in a recent session of the chemist. Over the month, the performance remains slightly negative (-0.73%), but the stock still holds a gain of 10.8% over three months.
The appointment of Laurent Tellier as Chief Operating Officer effective July 1, 2026, announced at the end of May, no longer drives the day's session. The movement is more explained by sectorial profit-taking in a market favoring growth stocks.
Technical Reversion Brings Stock to Its 20-Day Moving Average
The decline brings the stock price back to its 20-day moving average at €61.75 (a -0.32% difference), which has acted as a short-term arbiter for several sessions. Below this, the identified support at €59.20 serves as the next benchmark, while the 50-day moving average at €60.68 remains 1.43% below the current price, providing an intermediate cushion. The RSI at 59 remains neutral, indicating neither seller exhaustion nor buyer excess, leaving the stock in a technical arbitration zone without a clear signal. The 200-day moving average at €56.07 confirms a medium-term upward trend, with the price still about 10% above.
For the record, the first quarter accounts published on May 6 showed a 14% decline in EBITDA to 283 million euros, with margins under pressure, while the group maintained its target of slight EBITDA growth at constant exchange rates for the year. The performance of the 20-day moving average will be the next critical factor for the stock's short-term dynamics.
